These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30413050)

  • 1. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
    Tacelli M; Celsa C; Magro B; Giannetti A; Pennisi G; Spatola F; Petta S
    Pharmaceuticals (Basel); 2018 Nov; 11(4):. PubMed ID: 30413050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
    Iogna Prat L; Tsochatzis EA
    Hormones (Athens); 2018 Jun; 17(2):219-229. PubMed ID: 29858843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty liver disease in diabetes mellitus.
    Bhatt HB; Smith RJ
    Hepatobiliary Surg Nutr; 2015 Apr; 4(2):101-8. PubMed ID: 26005676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents.
    García-Compeán D; Kumar R; Cueto-Aguilera ÁND; Maldonado-Garza HJ; Villarreal-Pérez JZ
    Ann Hepatol; 2023; 28(4):100751. PubMed ID: 36002119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
    Sumida Y; Seko Y; Yoneda M;
    Hepatol Res; 2017 Mar; 47(4):266-280. PubMed ID: 28019064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
    Fruci B; Giuliano S; Mazza A; Malaguarnera R; Belfiore A
    Int J Mol Sci; 2013 Nov; 14(11):22933-66. PubMed ID: 24264040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.
    Ozturk ZA; Kadayifci A
    World J Hepatol; 2014 Apr; 6(4):199-206. PubMed ID: 24799988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus.
    Padda J; Khalid K; Khedr A; Tasnim F; Al-Ewaidat OA; Cooper AC; Jean-Charles G
    Cureus; 2021 Aug; 13(8):e17321. PubMed ID: 34557367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
    Kalogirou M; Sinakos E
    World J Hepatol; 2018 Nov; 10(11):790-794. PubMed ID: 30533179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.
    Carulli L; Maurantonio M; Hebbard L; Baldelli E; Loria P; George J
    Curr Pharm Des; 2013; 19(29):5280-96. PubMed ID: 23394096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease.
    Gouni-Berthold I; Papanas N; Maltezos E
    Curr Pharm Des; 2014; 20(22):3705-15. PubMed ID: 24040873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.
    Sofogianni A; Filippidis A; Chrysavgis L; Tziomalos K; Cholongitas E
    World J Hepatol; 2020 Aug; 12(8):493-505. PubMed ID: 32952876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Carbone LJ; Angus PW; Yeomans ND
    J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.